184 related articles for article (PubMed ID: 16042543)
1. Disease modifying strategies for the treatment of Alzheimer's disease targeted at modulating levels of the beta-amyloid peptide.
Pangalos MN; Jacobsen SJ; Reinhart PH
Biochem Soc Trans; 2005 Aug; 33(Pt 4):553-8. PubMed ID: 16042543
[TBL] [Abstract][Full Text] [Related]
2. Characterization of Abeta11-40/42 peptide deposition in Alzheimer's disease and young Down's syndrome brains: implication of N-terminally truncated Abeta species in the pathogenesis of Alzheimer's disease.
Liu K; Solano I; Mann D; Lemere C; Mercken M; Trojanowski JQ; Lee VM
Acta Neuropathol; 2006 Aug; 112(2):163-74. PubMed ID: 16865398
[TBL] [Abstract][Full Text] [Related]
3. [Recent progress in the development of disease-modifying therapies for Alzheimer's disease].
Abe K
Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Feb; 30(1):1-8. PubMed ID: 20297736
[TBL] [Abstract][Full Text] [Related]
4. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.
Hussain I; Hawkins J; Harrison D; Hille C; Wayne G; Cutler L; Buck T; Walter D; Demont E; Howes C; Naylor A; Jeffrey P; Gonzalez MI; Dingwall C; Michel A; Redshaw S; Davis JB
J Neurochem; 2007 Feb; 100(3):802-9. PubMed ID: 17156133
[TBL] [Abstract][Full Text] [Related]
5. [Therapy of Alzheimer disease].
Kovács T
Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
[TBL] [Abstract][Full Text] [Related]
6. The novel beta-secretase inhibitor KMI-429 reduces amyloid beta peptide production in amyloid precursor protein transgenic and wild-type mice.
Asai M; Hattori C; Iwata N; Saido TC; Sasagawa N; Szabó B; Hashimoto Y; Maruyama K; Tanuma S; Kiso Y; Ishiura S
J Neurochem; 2006 Jan; 96(2):533-40. PubMed ID: 16336629
[TBL] [Abstract][Full Text] [Related]
7. Expression and activity of beta-site amyloid precursor protein cleaving enzyme in Alzheimer's disease.
Johnston JA; Liu WW; Todd SA; Coulson DT; Murphy S; Irvine GB; Passmore AP
Biochem Soc Trans; 2005 Nov; 33(Pt 5):1096-100. PubMed ID: 16246054
[TBL] [Abstract][Full Text] [Related]
8. Amyloidogenic processing of beta-amyloid precursor protein in intracellular compartments.
Vetrivel KS; Thinakaran G
Neurology; 2006 Jan; 66(2 Suppl 1):S69-73. PubMed ID: 16432149
[TBL] [Abstract][Full Text] [Related]
9. The role of amyloid beta peptide 42 in Alzheimer's disease.
Findeis MA
Pharmacol Ther; 2007 Nov; 116(2):266-86. PubMed ID: 17716740
[TBL] [Abstract][Full Text] [Related]
10. Drugs targeting Alzheimer's disease: some things old and some things new.
Michaelis ML
J Pharmacol Exp Ther; 2003 Mar; 304(3):897-904. PubMed ID: 12604663
[TBL] [Abstract][Full Text] [Related]
11. Cholesterol and Alzheimer's disease--is there a relation?
Sjögren M; Mielke M; Gustafson D; Zandi P; Skoog I
Mech Ageing Dev; 2006 Feb; 127(2):138-47. PubMed ID: 16332384
[TBL] [Abstract][Full Text] [Related]
12. The experimental Alzheimer's disease drug posiphen [(+)-phenserine] lowers amyloid-beta peptide levels in cell culture and mice.
Lahiri DK; Chen D; Maloney B; Holloway HW; Yu QS; Utsuki T; Giordano T; Sambamurti K; Greig NH
J Pharmacol Exp Ther; 2007 Jan; 320(1):386-96. PubMed ID: 17003227
[TBL] [Abstract][Full Text] [Related]
13. Effects of peptides derived from BACE1 catalytic domain on APP processing.
Yeon SW; Jeon YJ; Hwang EM; Kim TY
Peptides; 2007 Apr; 28(4):838-44. PubMed ID: 17293005
[TBL] [Abstract][Full Text] [Related]
14. Herpes simplex virus infection causes cellular beta-amyloid accumulation and secretase upregulation.
Wozniak MA; Itzhaki RF; Shipley SJ; Dobson CB
Neurosci Lett; 2007 Dec; 429(2-3):95-100. PubMed ID: 17980964
[TBL] [Abstract][Full Text] [Related]
15. LRRTM3 promotes processing of amyloid-precursor protein by BACE1 and is a positional candidate gene for late-onset Alzheimer's disease.
Majercak J; Ray WJ; Espeseth A; Simon A; Shi XP; Wolffe C; Getty K; Marine S; Stec E; Ferrer M; Strulovici B; Bartz S; Gates A; Xu M; Huang Q; Ma L; Shughrue P; Burchard J; Colussi D; Pietrak B; Kahana J; Beher D; Rosahl T; Shearman M; Hazuda D; Sachs AB; Koblan KS; Seabrook GR; Stone DJ
Proc Natl Acad Sci U S A; 2006 Nov; 103(47):17967-72. PubMed ID: 17098871
[TBL] [Abstract][Full Text] [Related]
16. Molecular aspects of neurodegeneration in Alzheimer's disease.
Russo C; Venezia V; Salis S; Dolcini V; Schettini G
Funct Neurol; 2002; 17(2):65-70. PubMed ID: 12224792
[TBL] [Abstract][Full Text] [Related]
17. Abeta-degrading enzymes: modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention.
Eckman EA; Eckman CB
Biochem Soc Trans; 2005 Nov; 33(Pt 5):1101-5. PubMed ID: 16246055
[TBL] [Abstract][Full Text] [Related]
18. P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice.
Meredith JE; Thompson LA; Toyn JH; Marcin L; Barten DM; Marcinkeviciene J; Kopcho L; Kim Y; Lin A; Guss V; Burton C; Iben L; Polson C; Cantone J; Ford M; Drexler D; Fiedler T; Lentz KA; Grace JE; Kolb J; Corsa J; Pierdomenico M; Jones K; Olson RE; Macor JE; Albright CF
J Pharmacol Exp Ther; 2008 Aug; 326(2):502-13. PubMed ID: 18499745
[TBL] [Abstract][Full Text] [Related]
19. Novel heparan sulphate analogues: inhibition of beta-secretase cleavage of amyloid precursor protein.
Patey SJ; Yates EA; Turnbull JE
Biochem Soc Trans; 2005 Nov; 33(Pt 5):1116-8. PubMed ID: 16246059
[TBL] [Abstract][Full Text] [Related]
20. Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1.
Ohno M; Chang L; Tseng W; Oakley H; Citron M; Klein WL; Vassar R; Disterhoft JF
Eur J Neurosci; 2006 Jan; 23(1):251-60. PubMed ID: 16420434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
